Compare American Tower Corp (AMT) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Tower Corp vs Vertex Pharmaceuticals Incorporated — how do they compare? American Tower Corp trades at $169.8 (market cap $78.80B), while Vertex Pharmaceuticals Incorporated trades at $529 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and American Tower Corp pays a 4.13% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| AMT | VRTX | |
|---|---|---|
Market Cap | $78.80B | $132.79B |
Sector | Real Estate | Health |
52-Week High | $211.88 | $529.65 |
52-Week Low | $162.11 | $376.62 |
Enterprise Value | $122.32B | $126.92B |
Dividend Yield | 4.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American Tower (AMT) trades at $172.54, up 0.78% on the day, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $1.86 exceeding the $1.57 forecast. Revenue for 2025 reached $10.64 billion, with a robust net income margin of 26.81%. Analyst sentiment is overwhelmingly positive, with 39 of 49 analysts rating it a Buy and a consensus price target of $206.17, implying significant upside. Recent news highlights insider selling and upbeat analyst coverage.
The outlook for AMT is favorable, driven by resilient telecom demand, 5G/6G expansion, and double-digit growth in its data center segment. Key risks include sensitivity to interest rates, Dish Network churn impacts, and high debt levels. With strong cash flow from operations and a bullish analyst consensus, the stock presents a compelling opportunity for growth-oriented investors, though macroeconomic factors warrant monitoring.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Tower Corp
American Tower owns and operates more than 220,000 cell towers throughout the U.S., Asia, Latin America, Europe, and Africa. It also owns and/or operates 25 data centers in eight U.S. markets after acquiring CoreSite. On its towers, the company has a very concentrated customer base, with most revenue in each market being generated by just the top few mobile carriers. The company operates more than 40,000 towers in the U.S., which accounted for more than half of its total revenue in 2021. Outside the U.S., American Tower's greatest presence is in India and Brazil, where it operates roughly 75,000 and 19,000 towers, respectively. American Tower operates as a real estate investment trust.
Read more on AMT →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
